Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
to nexiguran ziclumeran (nex-z), NTLA's lead pipeline candidate. It is being developed in collaboration with Regeneron Pharmaceuticals REGN for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN). In October 2025, Intellia temporarily halted dosing and patient enrollment in its late-stage MAGNITUDE and MAGNITUDE-2 studies, which were evaluating nex-z, its lead gene-editing therapy, for treating two cardiovascular indications, ATTR-CM and ATTRv-PN, respectively. The studies were halted after a patient experienced grade 4 liver transaminase elevations and increased total bilirubin following dosing with nex-z and later died. This triggered a clinical hold from the FDA on the investigational new drug applications and raised widespread concerns about the safety and future of the program. With the formal clinical hold in place, Intellia has suspended its milestone guidance for nex-z and will provide an update once a reg
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]Yahoo! Finance
- Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 1/9/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- NTLA's page on the SEC website